Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Tocilizumab in KSHV-Associated Multicentric Castleman Disease
NCT01441063Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2011
- Primary completion
- Jun 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in multicentric Castleman disease (MCD), sponsored by National Cancer Institute. Primary endpoint: Percentage of Participants With an Overall Clinical Benefit Response up to 12 weeks. Started Sep 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT01441063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441063.